Propanc Biopharma Inc. (NASDAQ : PPCB ) News

Propanc Biopharma Inc. (NASDAQ: PPCB) News Releases

PPCB News Releases

March 24, 2026 08:45:00 am

GlobeNewswire

Propanc Biopharma Executes Multi-Yr, Anti-Aging & Cancer Research Collaboration with the Universities of Jaén and Granada, Spain

March 12, 2026 08:45:00 am

GlobeNewswire

Propanc Biopharma Targets $3B+ Pancreatic Cancer Market with PRP: 85%+ Tumor Inhibition in Breakthrough Proenzyme Therapy

March 10, 2026 08:45:00 am

GlobeNewswire

Propanc Biopharma Executes Service Agreement with FyoniBio to Establish & Validate Pharmacokinetics Assay for Phase 1b First-In-Human Study

March 03, 2026 08:45:00 am

GlobeNewswire

Propanc Biopharma's Lead Asset PRP Shows >85% Tumor Growth Inhibition in Preclinical Pancreatic Models

February 18, 2026 03:42:43 pm

SeekingAlpha

Propanc Biopharma, Inc. GAAP EPS of -$0.30

February 18, 2026 08:45:00 am

GlobeNewswire

Propanc Biopharma Provides Corporate Update and Reports Half Yearly 2025/26 Results

February 05, 2026 08:45:00 am

GlobeNewswire

Propanc Biopharma Unveils PRP: A Game-Changing Proenzyme Therapy Poised to Challenge Standard Cancer Treatments in the $3+ Billion Pancreatic Cancer Market

January 29, 2026 03:31:04 pm

QM US Market Movers News

US Companies Moving the Markets, Evening edition
Thu, Jan 29, 2026 as of 4:00 pm ET

January 29, 2026 09:01:03 am

QM US Market Movers News

US Companies Moving the Markets, Morning edition
Thu, Jan 29, 2026 as of 10.00 am ET

January 27, 2026 08:45:00 am

GlobeNewswire

Propanc Biopharma Accelerates IP Momentum: Files Fourth Provisional Patent Application in Just Two Months - Strengthening Global Protection for Breakthrough Proenzyme Formulations

Subscribe to Our Newsletter

Download The Market Wire News App

Link Market Wire News to Your X Account